118.97

0.42% -0.50

Sarepta Therapeutics Inc (SRPT)

Overview News Price History Option Chain Financials Why SRPT Down? Discussions Forecast Stock Split

Sarepta Therapeutics Inc stock is traded at $118.97, with a volume of 1.39M. It is down -0.42% in the last 24 hours and up +7.32% over the past month. Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.

Previous Close:

$119.47

Open:

$119.59

24h Volume:

1.39M

Relative Volume:

1.48

Market Cap:

$11.36B

Revenue:

$1.64B

Net Income/Loss:

$121.85M

P/E Ratio:

-15.19

EPS:

-7.83

Net Cash Flow:

$-480.40M

1W Performance:

-3.83%

1M Performance:

+7.32%

6M Performance:

-3.67%

1Y Performance:

+31.76%

1-Day Range:

$118.56

$121.00

1-Week Range:

$117.97

$128.73

52-Week Range:

$89.92

$173.25

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Name

Sarepta Therapeutics Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

617-274-4000

Address

215 FIRST STREET, CAMBRIDGE, MA

Employee

1,314

Twitter

@sarepta

Next Earnings Date

2024-11-06

Latest SEC Filings

SRPT's Discussions on Twitter

Compare SRPT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SRPT Sarepta Therapeutics Inc	118.97	11.36B	1.64B	121.85M	-480.40M	1.54
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-27-24	Reiterated	Needham	Buy
Nov-25-24	Initiated	H.C. Wainwright	Sell
Nov-07-24	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Oct-21-24	Initiated	Jefferies	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Jul-29-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jun-26-24	Downgrade	Citigroup	Buy → Neutral
May-31-24	Initiated	Piper Sandler	Overweight
May-28-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
May-14-24	Upgrade	Oppenheimer	Perform → Outperform
Jan-31-24	Initiated	BMO Capital Markets	Outperform
Dec-13-23	Resumed	Citigroup	Buy
Dec-12-23	Initiated	Deutsche Bank	Buy
Nov-21-23	Initiated	Wedbush	Outperform
Oct-31-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-31-23	Downgrade	Oppenheimer	Outperform → Perform
Jun-23-23	Downgrade	Evercore ISI	Outperform → In-line
Apr-26-23	Initiated	SMBC Nikko	Outperform
Apr-04-23	Initiated	Citigroup	Buy
Mar-01-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-22-22	Reiterated	BTIG Research	Buy
Dec-16-22	Upgrade	UBS	Neutral → Buy
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight
Jan-05-22	Reiterated	Needham	Buy
Dec-09-21	Upgrade	Oppenheimer	Perform → Outperform
Nov-05-21	Upgrade	JP Morgan	Neutral → Overweight
Sep-15-21	Upgrade	Guggenheim	Neutral → Buy
Aug-05-21	Upgrade	JP Morgan	Underweight → Neutral
Jun-15-21	Initiated	BTIG Research	Buy
Apr-26-21	Resumed	Credit Suisse	Neutral
Jan-12-21	Downgrade	Citigroup	Buy → Neutral
Jan-11-21	Downgrade	UBS	Buy → Neutral
Jan-08-21	Downgrade	JP Morgan	Overweight → Underweight
Jan-08-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-08-21	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-11-20	Initiated	Berenberg	Hold
Oct-28-20	Initiated	UBS	Buy
Aug-25-20	Initiated	Raymond James	Outperform
Aug-20-20	Downgrade	Credit Suisse	Outperform → Neutral
Mar-31-20	Initiated	Mizuho	Buy
Nov-01-19	Initiated	Guggenheim	Buy
Aug-21-19	Reiterated	Needham	Buy
Jul-09-19	Reiterated	Morgan Stanley	Overweight
Jul-01-19	Reiterated	RBC Capital Mkts	Outperform
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-11-19	Reiterated	Credit Suisse	Outperform
Oct-12-18	Initiated	Bernstein	Outperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Sep-26-18	Reiterated	RBC Capital Mkts	Outperform
Sep-14-18	Resumed	BofA/Merrill	Buy
Sep-06-18	Initiated	Credit Suisse	Outperform
Aug-01-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-21-18	Reiterated	Robert W. Baird	Outperform
Jun-20-18	Reiterated	Needham	Buy
Jun-19-18	Reiterated	H.C. Wainwright	Buy

View All

Sarepta Therapeutics Inc Stock (SRPT) Latest News

Dec 20, 2024

Nippon Owes $115M In Muscular Dystrophy IP Fight, Jury Says - Law360

Dec 20, 2024

Nippon Shinyaku Owes Sarepta $115 Million on Gene-Therapy Patent - Bloomberg Law

Dec 20, 2024

Sarepta Wins First Phase of Nippon Shinyaku Gene-Therapy Trial - Bloomberg Law

Dec 20, 2024

SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder - MSN

Dec 20, 2024

The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam - Yahoo Finance

Dec 20, 2024

Dec 19, 2024

Communiqué de presse - GlobeNewswire Inc.

Dec 19, 2024

Sarepta completes subject dosing in Phase III LGMD2E/R4 therapy trial - Yahoo Finance

Dec 19, 2024

Sarepta Therapeutics (NASDAQ:SRPT) Receives Sell Rating from HC Wainwright - MarketBeat

Dec 19, 2024

A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts - Benzinga

Dec 19, 2024

Even though Sarepta Therapeutics (NASDAQ:SRPT) has lost US$491m market cap in last 7 days, shareholders are still up 33% over 1 year - Simply Wall St

Dec 19, 2024

Dec 18, 2024

Sarepta Completes Pivotal Phase 3 Trial Enrollment for Groundbreaking Muscular Dystrophy Gene Therapy - StockTitan

Dec 18, 2024

National Bank of Canada FI Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 18, 2024

Dec 17, 2024

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 - Yahoo Finance

Dec 17, 2024

Dec 16, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Sells $1,310,820.00 in Stock - MarketBeat

Dec 16, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Geode Capital Management LLC - MarketBeat

Dec 16, 2024

Stifel Financial Corp Grows Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Dec 16, 2024

Sarepta Therapeutics' SWOT analysis: DMD leader's stock poised for growth - Investing.com

Dec 16, 2024

Dec 15, 2024

19,358 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bought by World Investment Advisors LLC - MarketBeat

Dec 15, 2024

Dec 14, 2024